ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

NCI grants funding: Institute Contemplates Increase In RFA Support Due to Large Number Of Grant Applications

July 9, 1999

Breast Cancer Progress Report Summaries

November 14, 1975

Benno Schmidt, 86, Cancer Act Advocate, Chairman Of MSKCC boards, Cancer Panel

October 29, 1999

ACS Adopts Principles As Basis For Reform Of Health Care System

July 17, 1992

Afinitor Suspension Approved For Rare Pediatric Brain Tumor

August 31, 2012

Ohio Legislature Gives $1 Million To Cancer Control

August 19, 1983